CSL (CSLLY) Growth Rank: 9 (As of Jul. 08, 2026) — 10% Below Median


CSLLY CSL Ltd CSLLY
73 GF Score
Price $21.44
GF Value $50.76
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is CSL Growth Rank?

CSL CSLLY -1.11% 73 Growth Rank is 9 as of Jul. 08, 2026, which is 10% below its 10-year median of 10.00. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $50.76 (Significantly Undervalued). The stock has 7 warning signs investors should review.

CSL has the Growth Rank of 9.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

CSLLY vs VRTX, REGN, ALNY: Growth Rank Comparison

For the Biotechnology subindustry, CSL's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSL Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's Growth Rank distribution charts can be found below:

* The bar in red indicates where CSL's Growth Rank falls into.


CSLLY
73GF Score
CSL Ltd CSLLY
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 9 mean?
CSL (CSLLY) has a Growth Rank of 9 as of Jul. 08, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on CSL and its competitors. This is 10% below median its historical median of 10.00. Over the past decade, CSL's Growth Rank has ranged from 6.00 to 10.00.
Is CSL's Growth Rank too high?
CSL's current Growth Rank of 9 is 10% below median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 10.00. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Growth Rank compare to VRTX and REGN?
CSL's Growth Rank of 9 can be compared against companies in the Biotechnology industry. Historically, CSL's own Growth Rank has ranged from 6.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on CSL and its competitors. CSL's current Growth Rank is 9, which is 10% below median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.76, compared to a current price of $21.44 — trading 57.8% below its estimated fair value. The current Growth Rank is 9, which is 10% below median its 10-year median of 10.00. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For CSL (CSLLY), the current Growth Rank is 9 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSL (CSLLY) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of $21.44 is trading 57.8% below its estimated GF Value™ of $50.76. GuruFocus considers CSL to be Significantly Undervalued.

Key valuation signals for CSLLY:

  • Growth Rank: 9 (10% below median its 10-year median of 10.00)
  • GF Value™: $50.76 vs. price of $21.44 (57.8% below fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSL Business Description

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score

Get the complete analysis for CSLLY

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.44
Price
$50.76
GF Value